January 2, 2018
Longevity Biotech Awarded $225K Phase I SBIR Contract from NHLBI/NIH to develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma
Longevity Biotech, Inc. (LBT) has been awarded a contract from the National Heart Lung and Blood Insititue (NHLBI) of the National Institude of Health (NIH), to further the progress of a novel asthma therapeutic in preclinical models.